Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer.
The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is up 4% YTD, and Novavax (NASDAQ:NVAX) stock sits at 41%. Moderna is decisively ahead of both peers.
Today’s catalyst is corporate, not clinical. Moderna announced a leadership restructuring to prepare for a wave of planned product launches in 2027 and 2028, and traders are treating it as a credibility signal for the pipeline.
Restructuring Frames a 2027-2028 Launch Pipeline
Moderna disclosed an expanded role for President Stephen Hoge and named Ester Banque as Chief Commercial Officer. Hoge now oversees R&D, Manufacturing, and Commercial operations across three franchises, a structure designed for commercial scale rather than research-stage biotech.
The reorganization lines up with a planned slate of up to three product launches by 2027-2028, including a flu-plus-COVID combination vaccine, a seasonal flu vaccine, and a norovirus vaccine. Investors are reading the move as Moderna preparing the operational backbone needed to commercialize multiple vaccines simultaneously.
The day’s enthusiasm also rides on a recently approved EU label for mCOMBRIAX, the world’s first flu-plus-COVID combo vaccine, and a key upcoming Prescription Drug User Fee Act (PDUFA) date of August 5 for the seasonal flu candidate mRNA-1010. Both reinforce the narrative that 2026 is the setup year and 2027-2028 is the payoff window.
Moderna Versus Pfizer and Novavax: The 2026 Scoreboard
The YTD scoreboard answers the headline question directly. Moderna stock at +94% is ahead of Novavax stock and crushing Pfizer stock in 2026 so far. The dispersion reflects three very different business profiles within one industry label.
Pfizer is a diversified pharma giant where vaccines are one slice of a large revenue book. The company’s Q1 2026 revenue was $14.45 billion, up 5% year over year (YoY), with Comirnaty revenue down 59% and Paxlovid revenue down 63%, offset by launched and acquired products. Pfizer’s 7% dividend yield anchors a steadier, lower-beta profile, which limits both upside and downside in a momentum tape.
Meanwhile, Novavax is in transition. The company is leaning on a Matrix-M adjuvant licensing model, including a $30 million upfront payment from Pfizer with up to $500 million in milestones, and Q1 2026 revenue of $139.51 million easily topped consensus. However, that royalty-driven model carries lower revenue scale than Moderna’s product-led path.
The Caution Inside a 94% Rally
Moderna stock isn’t without baggage. The company’s Q1 2026 included an $878 million non-recurring litigation charge tied to the Arbutus/Genevant patent settlement, which widened the GAAP loss to $1.34 billion. Wall Street has been slow to embrace the rebound, with an analyst average 1-year MRNA price target of $37 and a consensus rating of Reduce.
Zoom out and Moderna stock is still down 74% over five years, well below its pandemic-era peaks. The 2026 run is a rebound, not a return to those highs, and the 2027-2028 launch slate carries real execution and regulatory risks.
What to Watch Next
The near-term event to look for is the FDA advisory committee vote scheduled for June 18 on mFlusiva for adults 50 and older. A constructive panel readout could reinforce today’s bid, while a mixed verdict may test how much of the 94% YTD gain is priced for perfection.
Investors can watch whether Moderna stock holds the $50 zone into the June 18 advisory committee vote and the August 5 PDUFA decision. Until then, feel free to size your share vaccine-stock positions with due caution and moderation.
Top Gaining Stocks
Top Losing Stocks